This ‘Stuttering-Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the stuttering, historical and forecasted epidemiology as well as the stuttering market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The stuttering market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM stuttering market size from 2019 to 2032. The Report also covers current stuttering treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032
Childhood-onset fluency disorder, also known as stuttering or stammering, is a common multifactorial speech disorder. It is a disruption in the fluency of verbal expression characterized by involuntary, audible, or silent repetitions or prolongations of sounds or syllables. These are not readily controllable and may be accompanied by other movements and by emotions of negative nature such as fear, embarrassment, or irritation, and are normally seen with recurrent prolongations, reverberations, or blocks of sounds, syllables, phrases, or words.
As it is a disorder in the fluency of speech, in addition to involuntary repetition and prolongation of sounds and syllables, there is also “secondary stuttering behavior,” which occurs as a response to the core stuttering behavior. These can be further explained by the example of “flight behaviors”, varying from choosing synonyms for the feared words to opting for social isolation to avoid speaking and concealing the stuttering out of anxiety, frustration, and shame. There are also “fight behaviors” varying from unnatural eye-blinking to involuntary movement of the extremities.
Stuttering arises, in general, before age 6, usually between 2.5 and 4 years of age. The most common form of stuttering is referred to as developmental stuttering. This may be contrasted with other forms of stuttering, which, for instance, arise from a neurological condition, trauma or emotional stress. Clinical diagnosis typically measures the rates of stuttering disfluencies while reading or during free speech and can include the rate of ancillary symptoms, sometimes known as struggle behaviors, during speech. The disorder resolves in most individuals, either spontaneously or with the help of speech therapy; however, approximately 20-25% of cases do not resolve, leading to a condition known as persistent developmental stuttering, which affects about 1% of the general population.
Some aspects of stuttering are apparent, while others are not. A speech-language pathologist (SLP) can make a comprehensive and reliable diagnosis. Stuttering is more than disfluencies, so it is important to see an SLP for testing.
Different guidelines and expert committees have designated different parameters for classification of stuttering.
Stuttering is a DSM-V psychiatric condition for which there are no FDA-approved medications for treatment. Medications with dopamine-blocking activity have shown the most efficacy; however, they can be limited by their respective side-effect profiles. Other agents have been tried with limited efficacy, but newer medications with novel mechanisms are showing promise in the pharmacologic treatment of stuttering.
Speech therapy can teach the one affected how to slow down speech and learn to notice when they stutter. The person may speak very slowly and deliberately when beginning speech therapy, but they can work up to a more natural speech pattern over time.
Some people who stutter use electronic devices to help control fluency.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of stuttering, diagnosed prevalent cases of stuttering and gender-specific diagnosed prevalent cases of stuttering scenario of stuttering in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
The epidemiology segment also provides the stuttering epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The drug chapter segment of the stuttering report encloses the detailed analysis of stuttering marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the stuttering clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.
Ecopipam: Emalex Biosciences Inc.
Ecopipam (EBS-101) is an investigational first-in-class drug being evaluated in pediatric patients for the treatment of Tourette syndrome (TS) and childhood-onset fluency disorder (stuttering) in adults. Ecopipam selectively blocks the actions of the neurotransmitter dopamine at the D1 receptor. Emalex Biosciences Inc. is currently investigating therapies for TS in pediatric patients and childhood-onset fluency disorder - also known as stuttering - in adults.
List of products to be continued in the report…
Stuttering is a speech disorder characterized by repetition of sounds, syllables, or words; prolongation of sounds; and interruptions in speech known as blocks. Stuttering affects people of all ages, most often in children between the ages of 2 and 6 as they are developing their language skills. Although there is currently no cure for stuttering, there are a variety of treatments available. The nature of the treatment will differ based upon a person's age, communication goals, and other factors. It is crucial to work with a speech-language pathologist to determine the best treatment options.
For very young children, early treatment may prevent developmental stuttering from becoming a lifelong problem. Health professionals generally recommend that a child be evaluated if they have stuttered for 3-6 months, exhibit struggle behaviors associated with stuttering or have a family history of stuttering or related communication disorders. Some researchers recommend that a child be evaluated every 3 months to determine if stuttering is increasing or decreasing.
Drugs such as alprazolam (an antianxiety agent), citalopram (a selective serotonin reuptake inhibitor), and clomipramine (strongly serotonergic drug) have been reported to reduce stuttering in selective patients
There is no approved drug for the treatment of stuttering. Treatment often involves teaching parents about ways to support their child's production of fluent speech. There are many treatments for stuttering, however, none of the available treatments is 100% effective. Traditional speech therapy reduces the frequency and severity of a stutter and teaches stutterers to use effective communications skills.
This section provides the total stuttering market size and market size by therapies in the United States.
The total stuttering market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total stuttering market size and market size by therapies in Japan are provided.
This section focuses on the rate of uptake of the potential drugs recently launched in the stuttering market or expected to get launched in the market during the study period 2019-2032. The analysis covers the stuttering market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in phase II, and phase III stages also analyze key players involved in developing targeted therapeutics.
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for stuttering emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
The publisher performs competitively and market Intelligence analysis of the stuttering market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
The stuttering market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM stuttering market size from 2019 to 2032. The Report also covers current stuttering treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Stuttering Disease Understanding and Treatment Algorithm
Stuttering Overview
Childhood-onset fluency disorder, also known as stuttering or stammering, is a common multifactorial speech disorder. It is a disruption in the fluency of verbal expression characterized by involuntary, audible, or silent repetitions or prolongations of sounds or syllables. These are not readily controllable and may be accompanied by other movements and by emotions of negative nature such as fear, embarrassment, or irritation, and are normally seen with recurrent prolongations, reverberations, or blocks of sounds, syllables, phrases, or words.
As it is a disorder in the fluency of speech, in addition to involuntary repetition and prolongation of sounds and syllables, there is also “secondary stuttering behavior,” which occurs as a response to the core stuttering behavior. These can be further explained by the example of “flight behaviors”, varying from choosing synonyms for the feared words to opting for social isolation to avoid speaking and concealing the stuttering out of anxiety, frustration, and shame. There are also “fight behaviors” varying from unnatural eye-blinking to involuntary movement of the extremities.
Stuttering arises, in general, before age 6, usually between 2.5 and 4 years of age. The most common form of stuttering is referred to as developmental stuttering. This may be contrasted with other forms of stuttering, which, for instance, arise from a neurological condition, trauma or emotional stress. Clinical diagnosis typically measures the rates of stuttering disfluencies while reading or during free speech and can include the rate of ancillary symptoms, sometimes known as struggle behaviors, during speech. The disorder resolves in most individuals, either spontaneously or with the help of speech therapy; however, approximately 20-25% of cases do not resolve, leading to a condition known as persistent developmental stuttering, which affects about 1% of the general population.
Stuttering Diagnosis
Stuttering is usually diagnosed by a speech-language pathologist (SLP), a health professional trained to test and treat individuals with voice, speech, and language disorders. The SLP will consider a variety of factors, including the following:
- Child's case history (such as when the stuttering was first noticed and under what circumstances)
- An analysis of the child's stuttering behaviors
- An evaluation of the child's speech and language abilities and the impact of stuttering on their life
Some aspects of stuttering are apparent, while others are not. A speech-language pathologist (SLP) can make a comprehensive and reliable diagnosis. Stuttering is more than disfluencies, so it is important to see an SLP for testing.
Different guidelines and expert committees have designated different parameters for classification of stuttering.
Stuttering Treatment
Stuttering is a DSM-V psychiatric condition for which there are no FDA-approved medications for treatment. Medications with dopamine-blocking activity have shown the most efficacy; however, they can be limited by their respective side-effect profiles. Other agents have been tried with limited efficacy, but newer medications with novel mechanisms are showing promise in the pharmacologic treatment of stuttering.
Speech therapy can teach the one affected how to slow down speech and learn to notice when they stutter. The person may speak very slowly and deliberately when beginning speech therapy, but they can work up to a more natural speech pattern over time.
Some people who stutter use electronic devices to help control fluency.
Stuttering Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of stuttering, diagnosed prevalent cases of stuttering and gender-specific diagnosed prevalent cases of stuttering scenario of stuttering in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Key Findings
- Total prevalent cases of stuttering in the 7MM were found to be approximately 3,981,012 in 2021. These cases are expected to increase by 2032 at a CAGR of 0.4% during the study period (2019-2032).
- Among 7MM, the United States has the highest prevalent cases of stuttering with 1,636,434 cases in 2021.
- The total diagnosed prevalent cases of stuttering in the 7MM were observed to be 878,024 in 2021. These cases are expected to increase during the study period (2019-2032).
- A total of 409,108 diagnosed prevalent cases of stuttering were recorded in the US in 2021, these cases are expected to rise at a CAGR of 0.8% for the study period (2019-2032).
- Among the European countries, Germany had the highest diagnosed prevalent population of Stuttering with 88,573 cases, followed by the UK with 67,196 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
- In Japan, 132,528 diagnosed prevalent cases of stuttering were recorded in the year 2021.
- As per the publisher's assessment, for stuttering, the gender-specific distribution of the disease suggests male predominance with 658,518 cases while females were at a lower count with 219,506 cases in the 7MM.
Stuttering Epidemiology
The epidemiology segment also provides the stuttering epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Stuttering Drug Chapters
The drug chapter segment of the stuttering report encloses the detailed analysis of stuttering marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the stuttering clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.
Stuttering Emerging Drugs
Ecopipam: Emalex Biosciences Inc.
Ecopipam (EBS-101) is an investigational first-in-class drug being evaluated in pediatric patients for the treatment of Tourette syndrome (TS) and childhood-onset fluency disorder (stuttering) in adults. Ecopipam selectively blocks the actions of the neurotransmitter dopamine at the D1 receptor. Emalex Biosciences Inc. is currently investigating therapies for TS in pediatric patients and childhood-onset fluency disorder - also known as stuttering - in adults.
List of products to be continued in the report…
Stuttering Market Outlook
Stuttering is a speech disorder characterized by repetition of sounds, syllables, or words; prolongation of sounds; and interruptions in speech known as blocks. Stuttering affects people of all ages, most often in children between the ages of 2 and 6 as they are developing their language skills. Although there is currently no cure for stuttering, there are a variety of treatments available. The nature of the treatment will differ based upon a person's age, communication goals, and other factors. It is crucial to work with a speech-language pathologist to determine the best treatment options.
For very young children, early treatment may prevent developmental stuttering from becoming a lifelong problem. Health professionals generally recommend that a child be evaluated if they have stuttered for 3-6 months, exhibit struggle behaviors associated with stuttering or have a family history of stuttering or related communication disorders. Some researchers recommend that a child be evaluated every 3 months to determine if stuttering is increasing or decreasing.
Drugs such as alprazolam (an antianxiety agent), citalopram (a selective serotonin reuptake inhibitor), and clomipramine (strongly serotonergic drug) have been reported to reduce stuttering in selective patients
There is no approved drug for the treatment of stuttering. Treatment often involves teaching parents about ways to support their child's production of fluent speech. There are many treatments for stuttering, however, none of the available treatments is 100% effective. Traditional speech therapy reduces the frequency and severity of a stutter and teaches stutterers to use effective communications skills.
Key Findings
- The market size of stuttering in seven major markets was USD 40 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 13.4 % for the study period (2019-2032)
- The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of stuttering.
- Upcoming therapy, Ecopipam has the potential to create a significant positive shift in the stuttering market size.
- The United States accounts for the largest market size of Stuttering, in comparison to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
The United States Market Outlook
This section provides the total stuttering market size and market size by therapies in the United States.
EU-5 Market Outlook
The total stuttering market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total stuttering market size and market size by therapies in Japan are provided.
Stuttering Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the stuttering market or expected to get launched in the market during the study period 2019-2032. The analysis covers the stuttering market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Stuttering Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stages also analyze key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for stuttering emerging therapies.
Reimbursement Scenario in Stuttering
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
The publisher performs competitively and market Intelligence analysis of the stuttering market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of stuttering, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the stuttering epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for stuttering is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the stuttering market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Stuttering market.
Report Highlights
- The robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the stuttering market.
- The companies and academics are working to assess challenges and seek opportunities that could influence stuttering R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for stuttering. The launch of emerging therapies will significantly impact the stuttering market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Stuttering Report Insights
- Patient Population
- Therapeutic Approaches
- Stuttering Pipeline Analysis
- Stuttering Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Stuttering Report Key Strengths
- 11-Years Forecast
- The 7MM Coverage
- Stuttering Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Stuttering Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
Key Questions Answered
Market Insights:
- What was the stuttering market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the stuttering total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest stuttering market size during the forecast period (2022-2032)?
- At what CAGR, the stuttering market is expected to grow at the 7MM level during the forecast period (2022-2032)?
- What would be the stuttering market outlook across the 7MM during the forecast period (2022-2032)?
- What would be the stuttering market growth till 2032 and what will be the resultant market size in the year 2032?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden, and unmet needs of stuttering?
- What is the historical stuttering patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of stuttering at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to stuttering?
- Out of the above-mentioned countries, which country would have the highest population of stuttering during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
- Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of stuttering along with the approved therapy?
- What are the current treatment guidelines for the treatment of stuttering in the US and Europe?
- What are the stuttering marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of stuttering?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of stuttering?
- What are the key collaborations (Industry-Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the Stuttering therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for stuttering and their status?
- What are the key designations that have been granted for the emerging therapies for stuttering?
- What are the 7MM historical and forecasted market of stuttering?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving stuttering.
- To understand the future market competition in the stuttering market and an Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for stuttering in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the stuttering market.
- To understand the future market competition in the stuttering market.
Table of Contents
1. Key Insights2. Report Introduction4. Stuttering Market: Future Perspective5. Executive Summary of Stuttering8. Patient Journey11. KOL Views12. Market Drivers13. Market Barriers14. SWOT Analysis15. Unmet Needs16. Reimbursement and Market Access18. Publisher Capabilities19. Disclaimer20. About the Publisher
3. Stuttering Market Overview at a Glance
6. Disease Background and Overview: Stuttering
7. Epidemiology and Patient Population
9. Emerging Drugs
10. Stuttering: Seven Major Market Analysis
17. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Emalex Biosciences Inc.
